Skip to main content

Berger Franklin M's Form 4 filing

ESSA Pharma Inc. (EPIX) · filed Jan 5, 2023

Accession no.
0000899243-23-000914
Filed
Jan 5, 2023
Trade date
Dec 14-21, 2022
Filing delay
22 daysLate
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 7 non-derivative transactions. Open-market sales total $729.1K. It was filed 22 days after the trade, past the 2-business-day deadline.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Berger Franklin MCIK 0001273885Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Dec 14, 2022Common SharesSSaleDisposed−25,000$3.00−$75,000932,244Direct
Dec 15, 2022Common SharesSSaleDisposed−32,000$2.90−$92,800900,244Direct
Dec 15, 2022Common SharesSSaleDisposed−50,000$2.86−$143,000850,244Direct
Dec 16, 2022Common SharesSSaleDisposed−50,000$2.67−$133,500800,244Direct
Dec 20, 2022Common SharesSSaleDisposed−43,617$2.53−$110,351.01756,627Direct
Dec 21, 2022Common SharesSSaleDisposed−37,889$2.41−$91,312.49718,738Direct
Dec 21, 2022Common SharesSSaleDisposed−34,334$2.42−$83,088.28684,404Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

No transaction price on this filing refers to a footnote.

Read the full filing on SEC EDGAR (opens in a new tab)